Skip to main content
. 2022 May 9;8:61. doi: 10.1038/s41523-022-00423-z

Fig. 3. Cumulative incidence curves for BCFi and OS according to treatment arm.

Fig. 3

(a, b) Patients with LumA and (c, d) LumB tumours by PAM50. P-values from log rank test, Gehan’s version for BCFi, for maximum follow-up and for different time intervals. BCFi breast cancer-free interval, Lum Luminal, OS overall survival, TAM tamoxifen.